Technical Analysis for MPH - Mereo Biopharma Group Limited

Grade Last Price % Change Price Change
grade C 42.5 -4.49% -2.00
MPH closed down 4.49 percent on Friday, August 7, 2020, on 2 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical MPH trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness -4.49%
Oversold Stochastic Weakness -4.49%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.49%
Narrow Range Bar Range Contraction -4.49%
Inside Day Range Contraction -4.49%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Mereo BioPharma Group plc is a United Kingdom-based specialty biopharmaceutical company. The Company is engaged in the research and development of pharmaceuticals. It operates through three segments: Respiratory Unit, Endocrinology Disorders Unit and Orphan Diseases Unit. The Respiratory Unit segment develops drugs to treat respiratory diseases. The Endocrinology Disorders Unit segment develops drugs to treat endocrine disorders. The Orphan Diseases Unit segment develops drugs to treat various orphan diseases. It is engaged in the Phase II dose-ranging study with its oral anti-inflammatory agent, BCT-197, for treatment of the underlying inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Its product candidate, BPS-804, is in Phase II b/III study in patients with osteogenesis imperfecta (OI). It has initiated a Phase II b study with its oral aromatase inhibitor BGS-649 for the treatment of hypogonadal hypogonadism (HH) in obese men.
Chemistry Physical Sciences Pharmaceuticals Pharmaceutical Industry Biopharmaceutical Health Sciences Chronic Obstructive Pulmonary Disease Respiratory Diseases Medication Inflammation Organofluorides

Is MPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 75.0
52 Week Low 13.0
Average Volume 646,251
200-Day Moving Average 33.12
50-Day Moving Average 43.72
20-Day Moving Average 46.36
10-Day Moving Average 46.10
Average True Range 1.75
ADX 20.08
+DI 20.92
-DI 30.60
Chandelier Exit (Long, 3 ATRs ) 44.76
Chandelier Exit (Short, 3 ATRs ) 47.40
Upper Bollinger Band 49.92
Lower Bollinger Band 42.79
Percent B (%b) -0.04
BandWidth 15.39
MACD Line 0.19
MACD Signal Line 1.08
MACD Histogram -0.892
Fundamentals Value
Market Cap 56.36 Thousand
Num Shares 1.33 Thousand
EPS 13.00
Price-to-Earnings (P/E) Ratio 3.27
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 1.50
Dividend Yield 3.53%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.27
Resistance 3 (R3) 45.46 44.73 44.81
Resistance 2 (R2) 44.73 44.03 44.63 44.65
Resistance 1 (R1) 43.62 43.59 43.25 43.42 44.50
Pivot Point 42.89 42.89 42.70 42.79 42.89
Support 1 (S1) 41.77 42.18 41.41 41.58 40.50
Support 2 (S2) 41.04 41.74 40.94 40.35
Support 3 (S3) 39.93 41.04 40.19
Support 4 (S4) 39.73